Involucrin Antibodies

Involucrin (IVL)

Part of the insoluble cornified cell envelope (CE) of stratified squamous epithelia. .

Gene Information

Human
Gene Name:	IVL
Uniprot:	P07476
Entrez:	3713

Family

Belongs to:
involucrin family

Alternative Names

involucrin

Molecular Weight

Mass (kDA):
68.479 kDA

Genomic Context

Human
Location:	1q21.3
Sequence:	1; NC_000001.11 (152908545..152911886)

Tissue Specificity

Keratinocytes of epidermis and other stratified squamous epithelia.

Subcellular Localizations

Cytoplasm. Constituent of the scaffolding of the cornified envelope.

Diseases

• Lymphoma
• B-cell Lymphomas
• Vascular Neoplasms
• Angioendotheliomatosis
• Neoplasms
• Diffuse Large B-cell Lymphoma
• Malignant Paraganglionic Neoplasm
• Uterine Corpus Intravenous Leiomyomatosis
• Lymphohistiocytosis, Hemophagocytic
• Leiomyomatosis
• Uterine Fibroids
• Lymphoma, Non-hodgkin

• Histiocytosis Haematophagic
• Histiocytosis, Non-langerhans-cell
• Cell Invasion
• Pain
• Infarction
• Dermatitis

Interacting Proteins

• ACD

Pathways

• Pathogenesis
• Cell Adhesion
• Cell Cycle
• Keratinocyte Differentiation
• Conjugation
• Protein Sumoylation
• Immune Response
• Gluconeogenesis
• Tropism
• Cardiac Conduction
• Anaphase
• Reflex
• Cytokinesis

• Leukocyte Activation
• Glucose Homeostasis
• Chemotaxis
• Feeding Behavior
• Regulation Of Feeding Behavior
• Cell Chemotaxis
• Glucose Import

PTMs

• Sumoylation

• Cleavage

• Methylation

Research Areas

• Extracellular Matrix

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/IVL

Best Uses Of The IVL Marker

If you're looking for an IVL marker antibody, you've come to the right location. Boster Bio offers a wide range of antibodies, which include different platforms and verified positive and negative samples. These antibodies are highly specific and affinity-driven, and Boster rewards first reviewers with product credits. We hope you'll be one of their loyal customers as they continue to advance the field of IVL marker research.

Boster Bio Anti-Involucrin (Squamous Cell Terminal Differentiation Marker) Monoclonal Antibody

The Boster Bio Anti-Involucrin/IVL MonoclonalAntibody is an human antibody that reacts with an peptide that is specific to. The company manufactures this antibody under license from MedImmune LLC. The product is stored at -20°C for one year and can be stored in a freezer for up to six months. The product is comprised of 5 mg of bovine serum albumin and peptide sequences.

The IVL gene is responsible for involucrin, an essential protein in human skin. It is highly reactive and soluble , and is a substrate protein for transglutaminases. It is first seen in the cell's cell cytosol. It is cross-linked with membrane proteins to form an insoluble membrane under the plasma membrane. It is also involved in the assembly of the cornified envelope , and functions as a glutamyl donor in the process. Involucin is produced in the stratum spinosum. It is cross-linked to the protein by transglutaminase. The expression of the protein is decreased in cancers of the squamous layer, severe dysplasias (cervix and larynx) and in involucin.

Boster Bio Anti-Involucrin antibody recognizes the presence of peptides on human skin and other mammals. It recognizes Involucrin from pig, dog and owl monkey skins but not mouse skins. The antibody is highly specific anti-PD-L1 monoclonal antibody and therefore is suitable for use in many clinical research applications.

PEBP is a protein involved in the process of cell differentiation. It is responsible for the inhibition of calcium-induced cell growth. The treatment of calcium increased expression of involucrin however it did not alter loricrin. PEBP-mediated inhibition of cell proliferation is a common mechanism used to treat cancer stem cells.

PD-L1 was a target proteins in a variety of cancer cells. The SP263 antibody has high sensitivity and specificity against PD-1. It has a broad dynamic range and staining intensities are correlated to the PD-L1 levels. Transfected HEK cells showed differential staining of PD-L1.

The PD-L1 gene is present in a variety of cancers including head and neck squamous cell carcinoma. The immune system protects the tumor by blocking T cells' activity when PD-L1 expression is detected. Anti-Involucrin (Squamous Cell Terminal Differentiation Marker) Monoclonal Antibody is one of the most effective and first treatments for cancer patients who have this specific PD-1 expression.

The Phase 1/2 study of monoclonal PD-1 Antibody has shown promising results in patients with advanced NSCLC as well as HNSCC. The drug's negative predictive power was greater than its positive predictive power. The study also shows that the treatment works by targeting the PD-L1-expressing cells of the tumor.

A recent study reported that 1,25-Dihydroxyvitamin D3 inhibits proliferation and enhances differentiation in human keratinocytes in three different culture conditions. This could help us understand how immunosuppressive drugs affect human Keratinocytes. Although it's too early to definitively determine the role of PD-1 in cancer however, there are a lot of studies in progress to study its potential.

Boster Bio Anti-Macrosialin CD68 Antibody

This monoclonal antibody reacts with Human and Mouse in both IHC and WB assays. It has been validated for use on Human and Mouse samples in IHC-P applications. It can be used with or without blocking proteins and is not hazardous. The antibody is tested using known positive and negative samples, meaning you can use it with no fear of contamination.

The anti-CD68 antibody has several applications. It can be used to detect abnormal macrophages as well as histiocytic lymphoma. This antibody is able to detect circulating histiocytes within human blood and plasma. It can also assist in determining if a patient has an inherited condition, such as cancer or Lupus.

The Boster Bio Anti-MacrosialIn CD68 Antibody is highly specific and sensitive. It recognizes the human homolog of CD68 found in rats. It is also found in tissue macrophages and dendritic cell linings. These cells play a major role in the immune system, which includes the removal of foreign matter cells, extracellular cell-cell interactions and interactions between cells and pathogens.